Who can expect difficult competition in the biosimilars market?

A recent article at the Biotech Blog looks at a few of the segments they expect to see extensive competition in when it comes to the biosimilars market.

-Human growth hormones
-Recombinant insulins and modified recombinant insulins
-Follow-on versions of epoetin alfa
-Leukine®
-Drugs to combat neutropenia
-Interferon-alfa based treatments
-Rheumatoid arthritis treatments

Under current legislature, biologics automatically have 12 years of exclusivity, but after that, biosimilars can be introduced to the market. Do you agree that the areas above face the most competition? If not, what areas do you expect to see face competition?

Share this article with your social network, just click below to share now!

Share |